Lexeo Therapeutics, Inc. SEC filings LXEO

Lexeo Therapeutics, Inc. has 361 filings in SEC EDGAR's recent list, going back to Feb 4, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (acquisition or sale of assets, unregistered share sale). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Aug 12, 2026 Jun 30, 2026
10-Q Quarterly report May 11, 2026 Mar 31, 2026
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
10-Q/A Amended quarterly report May 15, 2025 Mar 31, 2025
10-Q Quarterly report May 12, 2025 Mar 31, 2025
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
10-Q Quarterly report Aug 12, 2024 Jun 30, 2024
10-Q Quarterly report May 9, 2024 Mar 31, 2024
10-Q Quarterly report Dec 11, 2023 Sep 30, 2023

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
LXEO (Nasdaq)
Fiscal year ends
December 31
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1907108

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.